专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明授权

US09107804B2 Method of preparing biologically active formulations 有权
标题翻译：制备生物活性制剂的方法
公开(公告)号：US09107804B2
公开(公告)日：2015-08-18
申请号：US10728196
申请日：2003-12-04
申请人： Orapin P. Rubino , David M. Jones , Peter Fankhauser , Armin Prasch , Karola Bretschneider
发明人： Orapin P. Rubino , David M. Jones , Frank Bretschneider , Peter Fankhauser , Armin Prasch
IPC分类号： A61K9/16 , A61J3/02
CPC分类号： A61K9/1652 , A61J3/02 , A61K9/1605 , A61K9/1635 , A61K9/4825 , A61K31/192 , A61K31/4402
摘要： The invention provides pellet for use as a core for a pharmaceutical dosage form having an inner and an outer zone where the inner zone includes a biologically active agent and said outer zone includes a layer formed by applying a substantially dry, free flowing inert powder which forms a non-tacky surface when placed in contact with water. The invention also provides a process for making pharmaceutical pellets where the core or at least one a layer on the core is formed by (a) contacting powder particles, adhering them to each other and compacting the adhered pellets by a rolling movement, wherein the degree of densification is controlled by the rolling movement; and (b) feeding a sufficient amount of a substantially dry, free flowing inert powder which forms a non-tacky surface when placed in contact with water to provide on said particles an outer zone including a layer formed from said substantially dry, free flowing inert powder.
摘要翻译：本发明提供用作药物剂型的核心的丸剂，其具有内部区域和外部区域，其中内部区域包括生物活性剂，所述外部区域包括通过施加基本上干燥的自由流动的惰性粉末形成的层，其形成当与水接触时是非粘性表面。本发明还提供一种制备药丸的方法，其中通过（a）使粉末颗粒彼此粘合并通过滚动运动使粘附的颗粒彼此粘合，从而形成芯或芯上至少一个层，其中度的致密化由滚动运动控制; 和（b）当放置与水接触时，供给足够量的基本干燥，自由流动的惰性粉末，其形成非粘性表面，以在所述颗粒上提供包含由所述基本上干燥，自由流动的惰性物质形成的层的外部区域粉末。

92. 发明申请

US20150225476A1 METHOD FOR TREATING A DISEASE OR DISORDER OF THE LUNG BY INHIBITION OF THE HEDGEHOG PATHWAY 审中-公开
标题翻译：通过对HEDGEHOG PATHWAY进行抑制来治疗肺疾病或疾病的方法
公开(公告)号：US20150225476A1
公开(公告)日：2015-08-13
申请号：US14430104
申请日：2013-09-23
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
发明人： Maria Alicia Curotto de Lafaille , Victor De Vries
IPC分类号： C07K16/18 , A61K39/395 , A61K45/06
CPC分类号： C07K16/18 , A61K9/0019 , A61K31/4355 , A61K31/4402 , A61K31/517 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K2317/76
摘要： The present invention is directed to a method of treating a disease or disorder characterised by one or more of the following: decreased lung function, bronchial hyper-responsiveness, hypersecretion of mucus, epithelial cell hyperplasia, smooth muscle hypertrophy, fibrosis or inflammation with an antagonist of a Hedgehog protein, an antagonist of Smoothened, or an antagonist of Gli. The present invention further provides kits for implementing the above method and the use of an antagonist of a Hedge-hog protein, an antagonist of Smoothened, or an antagonist of Gli for treating the above disease or disorder.
摘要翻译：本发明涉及一种治疗疾病或病症的方法，其特征在于以下一种或多种：肺功能降低，支气管高反应性，粘液过度分泌，上皮细胞增生，平滑肌肥大，纤维化或与拮抗剂的炎症的刺猬蛋白，Smoothened的拮抗剂或Gli的拮抗剂。本发明还提供了用于实施上述方法的试剂盒和Hedge-hog蛋白质拮抗剂，Smoothened拮抗剂或Gli拮抗剂用于治疗上述疾病或病症的用途。

93. 发明申请

US20150224108A1 AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE 审中-公开
标题翻译：水解调节剂及其用于治疗EDEMA和流体不平衡的方法
公开(公告)号：US20150224108A1
公开(公告)日：2015-08-13
申请号：US14678818
申请日：2015-04-03
申请人： THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
发明人： Gary A. Flynn , Andrea J. Yool , Elton Rodrigues Migliati , Leslie S. Ritter
IPC分类号： A61K31/54 , A61K31/24 , A61K31/495 , A61K31/5375 , A61K31/341 , A61K31/4402 , A61K31/4409 , A61K31/443 , A61K31/496 , A61K31/196 , A61K31/4406
CPC分类号： A61K31/54 , A61K31/196 , A61K31/24 , A61K31/341 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/443 , A61K31/495 , A61K31/496 , A61K31/5375 , C07C311/16 , C07C311/39 , C07D213/16 , C07D213/40 , C07D213/75 , C07D239/91 , C07D241/04 , C07D265/30 , C07D279/12 , C07D307/36 , C07D307/52 , C07D405/06 , C07D405/12 , C07D407/12
摘要： Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
摘要翻译：激动或拮抗水通道蛋白通道的化合物，包括3-羧基芳基磺酰胺化合物，以及使用它们治疗由水通道蛋白介导的疾病或疾病的方法。

94. 发明申请

US20150118301A1 Immediate Release Abuse-Deterrent Granulated Dosage Forms 审中-公开
公开(公告)号：US20150118301A1
公开(公告)日：2015-04-30
申请号：US14477354
申请日：2014-09-04
申请人： CIMA LABS INC.
发明人： Dinesh K. Haswani , Derek V. Moe , Victoria A. O'Neill , Manuel A. Vega Zepeda
IPC分类号： A61K9/48 , A61K31/485 , A61K31/515 , A61K31/165 , A61K31/4458 , A61K31/135 , A61K31/437 , A61K31/554 , A61K31/137 , A61K9/20 , A61K31/5513
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1676 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2063 , A61K9/2081 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5047 , A61K9/5078 , A61K31/135 , A61K31/137 , A61K31/16 , A61K31/165 , A61K31/167 , A61K31/192 , A61K31/437 , A61K31/4402 , A61K31/4458 , A61K31/515 , A61K31/5513 , A61K31/554 , A61K31/616 , A61K2300/00
摘要： Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.

95. 发明申请

US20150105433A1 TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM 审中-公开
标题翻译：治疗病毒感染的病毒RNA由非转染的介质机制翻译
公开(公告)号：US20150105433A1
公开(公告)日：2015-04-16
申请号：US14397396
申请日：2013-04-25
申请人： THE UAB RESEARCH FOUNDATION
发明人： Sunnie R. Thompson
IPC分类号： C07D277/46 , C07C235/56 , C12Q1/68 , C07C219/28 , C07D231/12 , C07D213/74 , C07D213/52
CPC分类号： C07D277/46 , A61K31/167 , A61K31/415 , A61K31/426 , A61K31/4402 , A61K31/7088 , C07C219/28 , C07C235/56 , C07D213/52 , C07D213/74 , C07D231/12 , C12N15/113 , C12Q1/6876 , C12Q2600/158 , Y02A50/385 , Y02A50/387 , Y02A50/393 , C12N2310/14 , C12N2310/531
摘要： Provided herein are methods for preventing or treating a viral infection in a subject, wherein the viral infection is mediated by a virus comprising one or more viral RNA molecules translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism. The methods comprise administering to a subject an agent that reduces ribosomal protein (Rps25) expression or function. Also provided are methods of inhibiting or promoting ribosomal shunting-mediated translation or non-IRES mediated translation. Also provided are methods of screening for an agent that inhibits or promotes ribosomal shunting-mediated translation or non-IRES mediated translation.
摘要翻译：本文提供了用于预防或治疗受试者中的病毒感染的方法，其中病毒感染由包含由核糖体分流机制翻译的一种或多种病毒RNA分子或非IRES介导的机制的病毒介导。所述方法包括向受试者施用降低核糖体蛋白（Rps25）表达或功能的试剂。还提供了抑制或促进核糖体分流介导的翻译或非IRES介导的翻译的方法。还提供了筛选抑制或促进核糖体分流介导的翻译或非IRES介导的翻译的试剂的方法。

96. 发明授权

US09005652B2 Chewable tablet containing phenylephrine 有权
标题翻译：含有去氧肾上腺素的咀嚼片
公开(公告)号：US09005652B2
公开(公告)日：2015-04-14
申请号：US11492656
申请日：2006-07-25
申请人： Josephine Fubara , Mark Mabry , Aaron Lewis Durr , Angela Taylor , Amanda Alley , David H. Giamalva , Manish Agrawal
发明人： Josephine Fubara , Mark Mabry , Aaron Lewis Durr , Angela Taylor , Amanda Alley , David H. Giamalva , Manish Agrawal
IPC分类号： A61K9/20 , A61K31/137 , A61K9/00
CPC分类号： A61K31/137 , A61K9/0056 , A61K31/4402
摘要： A chewable pharmaceutical composition comprising phenylephrine, artificial sweetener, and a substantially aldehyde-free matrix is provided. The composition has phenylephrine stability suitable for a typical commercial product with a two year shelf life. A method of manufacture of the composition and a method of use are also provided.
摘要翻译：提供了包含去氧肾上腺素，人造甜味剂和基本上不含醛的基质的可咀嚼的药物组合物。该组合物具有适用于具有两年保质期的典型商业产品的苯肾上腺素稳定性。还提供了组合物的制造方法和使用方法。

97. 发明授权

US09000179B2 Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) 有权
标题翻译：信号转导和转录激活因子（STAT）的增殖和激活抑制剂
公开(公告)号：US09000179B2
公开(公告)日：2015-04-07
申请号：US14103619
申请日：2013-12-11
申请人： Board of Regents, The University of Texas System
发明人： Waldemar Priebe , Stanislaw Skora , Timothy Madden , Izabela Fokt , Charles Conrad
IPC分类号： C07D213/57 , A61K31/44 , A61K31/4402 , C07D213/61
CPC分类号： C07D213/57 , A61K31/4402 , C07D213/61
摘要： Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
摘要翻译：提供了有效调节STAT3和/或STAT5活化的吡啶化合物，其可用于预防和治疗增殖性疾病和病症，包括癌症，炎症和增殖性皮肤病。

98. 发明授权

US08993808B2 Phenylcyclopropylamine derivatives and their medical use 有权
标题翻译：苯基环丙胺衍生物及其用途
公开(公告)号：US08993808B2
公开(公告)日：2015-03-31
申请号：US13138143
申请日：2010-01-21
申请人： Nathalie Guibourt , Alberto Ortega Munoz , Julio Castro-Palomino Laria
发明人： Nathalie Guibourt , Alberto Ortega Munoz , Julio Castro-Palomino Laria
IPC分类号： C07C211/40 , C07D213/38 , C07C217/58 , C07C217/74 , C07C255/58 , C07D213/61 , C07D277/28 , C07D333/20 , C07D333/28
CPC分类号： A61K31/137 , A61K31/14 , A61K31/277 , A61K31/343 , A61K31/353 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/4045 , A61K31/4245 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , C07C211/40 , C07C217/58 , C07C217/74 , C07C255/58 , C07C2601/02 , C07D213/38 , C07D213/61 , C07D277/28 , C07D333/20 , C07D333/28 , C12Q1/26 , G01N2500/04 , G01N2500/20
摘要： The present invention relates to phenylcyclopropylamine derivatives. In particular, pharmaceutical compositions comprising phenylcyclopropylamine derivatives are provided. The compounds of this invention can, inter alia, be used for the treatment and the prevention of cancer as well as neurodegenerative diseases or disorders.
摘要翻译：本发明涉及苯基环丙基胺衍生物。特别地，提供了包含苯基环丙基胺衍生物的药物组合物。本发明的化合物尤其可用于治疗和预防癌症以及神经变性疾病或病症。

99. 发明授权

US08980296B2 Compositions and methods for preventing cardiac arrhythmia 有权
标题翻译：用于预防心律失常的组合物和方法
公开(公告)号：US08980296B2
公开(公告)日：2015-03-17
申请号：US12707427
申请日：2010-02-17
申请人： Robert G. Matheny , Beecher C. Lewis
发明人： Robert G. Matheny , Beecher C. Lewis
IPC分类号： A61K35/12 , A61K35/34 , A61K35/36 , A61K38/18 , A61K38/20 , A61K38/21 , A61K38/48
CPC分类号： A61K35/407 , A61K9/0012 , A61K31/138 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/216 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/4166 , A61K31/439 , A61K31/44 , A61K31/4402 , A61K31/4418 , A61K31/4458 , A61K31/47 , A61K31/505 , A61K31/5377 , A61K31/5415 , A61K35/12 , A61K35/22 , A61K35/34 , A61K35/36 , A61K35/38 , A61K35/50 , A61K38/1825 , A61K38/1841 , A61K38/202 , A61K38/2026 , A61K38/2066 , A61K38/2086 , A61K38/2093 , A61K38/217 , A61K38/48 , A61K45/06 , A61L27/3633 , A61L27/3834 , A61L27/54
摘要： Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.
摘要翻译：本文公开了用于治疗或预防受试者心律失常的组合物和方法。

100. 发明申请

US20150072020A1 Dexanabinol or a Derivative Thereof for Use in the Treatment of Cancer in Dose Ranges of 2-30 mg/kg 审中-公开
标题翻译：德西那尼醇或其衍生物用于2-30mg / kg剂量范围内的癌症治疗
公开(公告)号：US20150072020A1
公开(公告)日：2015-03-12
申请号：US14395541
申请日：2013-04-26
申请人： E-THERAPEUTICS PLC
发明人： Malcolm Philip Young , Philip McKeown
IPC分类号： A61K31/352 , A61K31/573 , A61N7/00 , A61K31/131 , A61K31/4402 , A61K45/06 , A61K31/341
CPC分类号： A61K31/352 , A61K31/131 , A61K31/341 , A61K31/4402 , A61K31/573 , A61K45/06 , A61N7/00
摘要： There is described a method of treating cancer in a patient wherein the method comprises the administration of dexanabinol, or a derivative thereof, in an amount of from about 2 mg/kg to about 30 mg/kg, based on the weight of the patient.
摘要翻译：描述了一种在患者体内治疗癌症的方法，其中所述方法包括基于患者体重施用约2mg / kg至约30mg / kg的右美沙芬或其衍生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式